STOCK TITAN

Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Harrow, Inc. has issued $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 in a private offering. These New Notes were sold to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.

The New Notes are fungible with Harrow’s existing $250,000,000 aggregate principal amount of 8.625% Senior Notes due 2030 and were issued under the same indenture. Harrow received approximately $48.7 million in net proceeds and plans to use the funds for general corporate purposes, including growth initiatives, product development, strategic business opportunities and related investments.

Positive

  • None.

Negative

  • None.

Insights

Harrow adds $50M of 8.625% 2030 notes, expanding its existing issue.

Harrow completed a private offering of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030, tapping the same indenture that governs $250,000,000 of existing notes at the same coupon and maturity.

The notes were placed with qualified institutional buyers under Rule 144A and certain non-U.S. investors under Regulation S, a standard structure for high-yield style debt. The company reports approximately $48.7 million in net proceeds after discounts and estimated expenses.

Harrow states it intends to use the proceeds for general corporate purposes, including growth initiatives, new product launches, upcoming product development and future strategic business development opportunities. Actual impact on leverage and interest coverage would depend on its broader financial profile, which is not detailed in this disclosure.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
false 0001360214 0001360214 2026-03-24 2026-03-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 24, 2026

 

HARROW, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35814   45-0567010

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1A Burton Hills Blvd., Suite 200    
Nashville, Tennessee   37215
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (615) 733-4730

 

  Not Applicable  
  (Former Name or Former Address, if Changed Since Last Report)  

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name on exchange on which registered
Common Stock, $0.001 par value per share   HROW   The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company

 

If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry Into a Material Definitive Agreement

 

Purchase Agreement

 

On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”). The terms of the New Notes sold pursuant to the Purchase Agreement are summarized below. The Purchase Agreement contains customary representations, warranties and covenants by the Company, together with customary closing conditions. Under the terms of the Purchase Agreement, the Company agreed to indemnify the Initial Purchasers against certain liabilities.

 

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is filed hereto, as Exhibit 10.1 and incorporated by reference herein.

 

Indenture

 

On March 27, 2026, the Company, the subsidiary guarantors named therein (the “Guarantors”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), entered into a First Supplemental Indenture (the “First Supplemental Indenture”) to the Indenture, dated September 12, 2025 (the “Base Indenture” and, together with the First Supplemental Indenture, the “Indenture”) pursuant to which the Company issued the New Notes.

 

The New Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 8.625% Senior Notes due 2030 that were issued by the Company on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.

 

The foregoing description of the First Supplemental Indenture and the New Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Base Indenture, the form of Global Note attached as Exhibit A thereto, and the First Supplemental Indenture, copies of which are filed hereto as Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3, respectively, and incorporated by reference herein.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

 

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference to the extent applicable.

 

Item 8.01. Other Events.

 

On March 27, 2026, the Company completed the sale of the New Notes in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.

 

The Company received net proceeds from the Offering, after deducting the Initial Purchasers’ discounts and estimated offering expenses and fees payable by the Company, of approximately $48.7 million. The Company intends to use the net proceeds from the Offering for general corporate purposes, which may include funding initiatives to accelerate growth (e.g., new product launches), funding upcoming product development activities, future strategic business development opportunities, and related investments.

 

This Current Report on Form 8-K shall not constitute an offer to sell, a solicitation of an offer to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer or solicitation will be made only by means of a confidential offering memorandum.

 

 

 

 

Cautionary Statement Regarding Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including statements regarding the use of proceeds of the New Notes. These statements are based on currently available operating, financial, economic and other information, and are subject to a number of significant risks and uncertainties. A variety of factors, many of which are beyond our control, could cause actual future results to differ materially from those projected in the forward-looking statements. Specific factors that might cause such a difference include, but are not limited to: changes in operations, business, financial or other conditions relevant to the planned transactions, and other execution risks related to the completion of the transactions described herein, as well as other risks detailed in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. We believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, we may not be able to complete the potential transactions on terms expected or at all, and our actual results may differ significantly from those expected or implied by our forward-looking statements. These and other risks are detailed in our filings with the Securities and Exchange Commission. We do not undertake any obligation to publicly update or revise these forward-looking statements after the date of this Current Report on Form 8-K to reflect future events or circumstances, except as required by applicable law. We qualify any and all of our forward-looking statements by these cautionary factors.

 

Item 9.01. Financial Statements and Exhibits

 

(d)   Exhibits
     
4.1   Indenture, dated September 12, 2025, by and among the Company, the guarantors named therein and U.S. Bank Trust Company, National Association, as trustee (a)
     
4.2   Form of 8.625% Senior Note due 2030 (included in Exhibit 4.1)
     
4.3   First Supplemental Indenture, dated as of March 27, 2026, by and between the Company, the guarantors named therein and U.S. Bank Trust Company, National Association, as trustee
     
10.1   Purchase Agreement, dated March 24, 2026, by and among the Company, the guarantors named therein and BTIG, LLC, as representative of the several initial purchasers named therein
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

(a)Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed September 12, 2025 (File No. 001-35814)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HARROW, INC.
   
Dated: March 27, 2026 By: /s/ Andrew R. Boll
    Andrew R. Boll
    President and Chief Financial Officer

 

 

FAQ

What type of financing did Harrow (HROW) complete in this 8-K?

Harrow completed a private offering of additional 8.625% Senior Notes due 2030 totaling $50.0 million in aggregate principal amount. The notes were sold to qualified institutional buyers and certain non-U.S. investors under Rule 144A and Regulation S.

How much cash did Harrow (HROW) receive from the new notes offering?

Harrow reports net proceeds of approximately $48.7 million from the sale of the New Notes. This figure is after deducting initial purchasers’ discounts and estimated offering expenses and fees payable by the company in connection with the transaction.

What are the terms of Harrow’s new senior notes issued in March 2026?

The New Notes are 8.625% Senior Notes due 2030 and are issued as additional notes under the same indenture as Harrow’s existing 8.625% Senior Notes due 2030, sharing the same terms other than issuance date and issue price.

How do the new Harrow (HROW) notes relate to its existing 2030 notes?

The New Notes are issued under the same indenture as Harrow’s existing $250,000,000 8.625% Senior Notes due 2030. They are treated as a single series with the existing notes, meaning they rank equally and share substantially identical terms.

How does Harrow intend to use the proceeds from the $50M notes offering?

Harrow intends to use the approximately $48.7 million in net proceeds for general corporate purposes. These may include growth initiatives such as new product launches, upcoming product development activities, strategic business development opportunities, and related investments.

Who purchased Harrow’s new 8.625% Senior Notes due 2030?

The New Notes were sold in a private offering to persons reasonably believed to be qualified institutional buyers in the United States under Rule 144A and to certain non-U.S. persons in offshore transactions pursuant to Regulation S under the Securities Act.

Filing Exhibits & Attachments

5 documents
Harrow Health Inc

NASDAQ:HROW

View HROW Stock Overview

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.32B
31.07M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE